 |
| |
| Apr-10-19 | Resumed |
Raymond James |
Mkt Perform |
|
|
| Mar-25-19 | Reiterated |
H.C. Wainwright |
Buy |
$363 → $300 |
|
| Mar-22-19 | Reiterated |
BMO Capital Markets |
Market Perform |
$322 → $250 |
|
| Mar-22-19 | Downgrade |
UBS |
Buy → Neutral |
$395 → $242 |
|
| Mar-22-19 | Downgrade |
Morgan Stanley |
Overweight → Underweight |
$401 → $210 |
|
| Mar-22-19 | Downgrade |
Canaccord Genuity |
Buy → Hold |
$396 → $275 |
|
| Mar-21-19 | Reiterated |
Guggenheim |
Neutral |
$325 |
|
| Mar-21-19 | Downgrade |
William Blair |
Outperform → Mkt Perform |
|
|
| Mar-21-19 | Downgrade |
Wells Fargo |
Outperform → Market Perform |
|
|
| Mar-21-19 | Downgrade |
Mizuho |
Buy → Neutral |
|
|
| Mar-21-19 | Downgrade |
JP Morgan |
Overweight → Neutral |
|
|
| Mar-21-19 | Downgrade |
Goldman |
Buy → Neutral |
|
|
| Mar-21-19 | Downgrade |
Citigroup |
Buy → Neutral |
|
|
| Mar-21-19 | Downgrade |
BofA/Merrill |
Buy → Neutral |
|
|
| Mar-21-19 | Downgrade |
Atlantic Equities |
Overweight → Neutral |
|
|
| Feb-21-19 | Downgrade |
Stifel |
Buy → Hold |
$397 → $346 |
|
| Dec-21-18 | Initiated |
BTIG Research |
Buy |
|
|
| Oct-19-18 | Downgrade |
Bernstein |
Outperform → Mkt Perform |
|
|
| Oct-08-18 | Reiterated |
Citigroup |
Buy |
$483 → $470 |
|
| Oct-01-18 | Resumed |
Cantor Fitzgerald |
Overweight |
$400 |
|
|
|
| Apr-18-19 10:29AM | Roche's (RHHBY) Q1 Sales Strong on Solid Demand for New Drugs Zacks |
| Apr-17-19 02:34PM | Here's Why Ionis Pharmaceuticals Slumped Today Motley Fool |
| 01:45PM | 2 Beaten Down Bluechips: Are They Buys? Motley Fool |
| 10:31AM | Biogen (BIIB) Reports Next Week: Wall Street Expects Earnings Growth Zacks |
| Apr-15-19 05:45PM | Biogen (BIIB) Dips More Than Broader Markets: What You Should Know Zacks |
| 03:00PM | Seeking $86 million IPO, this Peninsula company is betting common bacteria plays role in Alzheimer's American City Business Journals |
| 06:58AM | Goldman Sachs's 20 best stocks to invest in now Yahoo Finance |
| Apr-14-19 09:16AM | Better Buy: Gilead Sciences vs. Biogen Motley Fool |
| Apr-12-19 07:30AM | Biogen Continues to Advance Innovation in SMA with New Data in Adults and Infants to Be Presented at MDA Clinical and Scientific Conference GlobeNewswire |
| Apr-11-19 06:33AM | Risk-Tolerant Investors, Turn Your Eyes to Exelixis Stock InvestorPlace |
| 12:00AM | An AI Firm Wants to Predict Costly Pharma Flops Bloomberg |
| Apr-10-19 09:59AM | Raymond James: Biogen's Business Appears Fragile, Faces Many Headwinds Benzinga |
| Apr-09-19 05:45PM | Biogen (BIIB) Dips More Than Broader Markets: What You Should Know Zacks |
| 05:01PM | 6 Predictable Guru Stocks GuruFocus.com |
| Apr-07-19 11:59PM | Sarissa Capital Management Hires New President Insider Monkey |
| Apr-06-19 06:13PM | Should Biogen Investors Be Extra Nervous Right Now? Motley Fool |
| Apr-04-19 03:54PM | Here's What Biogen Inc.'s (NASDAQ:BIIB) P/E Ratio Is Telling Us Simply Wall St. |
| 02:49PM | 1 Biotech That Biogen Should Buy ... but Probably Won't Motley Fool |
| 01:28PM | Buy Biogen on the dip? What about AMC on the streaming wars? The viewers #AskHalftime CNBC Videos |
| 09:57AM | Why Biogen Stock Tanked in March Motley Fool |
| 09:03AM | MOVES-Activist hedge fund Sarissa hires president in push for growth Reuters |
| Apr-03-19 06:08PM | Biogen SMA drug price, Novartis estimates for its treatment far too high: U.S. group Reuters |
| 05:41PM | Biogen SMA drug price, Novartis estimates for its treatment far too high -U.S. group Reuters |
| 04:37PM | Biogen SMA drug price, Novartis estimates for its treatment far too high -U.S. group Reuters |
| 08:21AM | Why Nightstar Therapeutics Stock Skyrocketed 71% in March Motley Fool |
| Apr-02-19 11:58AM | 3 Healthcare Stocks to Trade Now InvestorPlace |
| 10:10AM | Will Biogen (BIIB) Beat Estimates Again in Its Next Earnings Report? Zacks |
| Apr-01-19 04:24PM | Celgene Gets Positive CHMP Nod for Revlimid Label Expansion Zacks |
| 02:56PM | These are the 20 most valuable brands in Massachusetts American City Business Journals |
| 01:46PM | 3 High Earnings-Yield Stocks GuruFocus.com |
| 10:41AM | Merck KgaA's (MKGAF) MS Drug Mavenclad Gets FDA Approval Zacks |
| Mar-30-19 12:00PM | 3 Leading Alzheimer's Disease Drugs in Development After Biogen's Aducanumab Flop Motley Fool |
| 05:46AM | Are the health care stocks flat lining? Here are the beaten down names traders are still buying CNBC Videos |
| Mar-29-19 10:36AM | 4 Small Biotech Stocks Likely to Witness More Upside in 2019 Zacks |
| Mar-28-19 04:34PM | Is Biogen a Beat-Up Bargain? And Is Bristol-Myers' Mega-Merger on the Rocks? Motley Fool |
| 12:04PM | Why Biogen's Alzheimer's Drug Failure May Have a Silver Lining Motley Fool |
| Mar-27-19 07:19PM | The 5 Worst-Performing Stocks in the S&P 500 in 2019 GuruFocus.com |
| 07:07PM | 3 High-Quality, Low Price-Earnings Companies Broadly Owned by Gurus GuruFocus.com |
| 06:50PM | Is Biogen Inc. (BIIB) A Good Stock To Buy? Insider Monkey |
| 06:13PM | Novartis (NVS) Receives FDA Approval for MS Drug Mayzent Zacks |
| 04:12PM | The Hits Just Keep Coming For Biogen As Rival Gains MS Drug Approval Investor's Business Daily |
| 10:55AM | Biotech Stock Roundup: BIIB & CNAT Crash on Study Failures, LXRX Gets CRL Zacks |
| 10:00AM | Future Brightens for 2 Small Biotech Stocks TheStreet.com |
| 07:00AM | Biogen Remains a Wide-Moat Neurology Innovator Morningstar |
| 06:00AM | Biogen- A Bad News Biotech Buy MoneyShow |
| Mar-26-19 05:15PM | Celgene (CELG) Submits NDA for MS Drug to FDA for Review Zacks +5.74% |
| 04:28PM | Why Viacom, Ferroglobe, and Biogen Jumped Today Motley Fool |
| 12:51PM | Stocks - Dow Ends Higher, but Gains Capped by Weak Economic Data Investing.com |
| 11:18AM | AbbVie's Psoriasis Drug Skyrizi Gets First Approval in Japan Zacks |
| 10:24AM | Biogen's Bad News for Everyone Motley Fool |
| 07:25AM | Detailed Research: Economic Perspectives on Biogen, Invesco, Bunge, Concho Resources, Maximus, and Meredith What Drives Growth in Today's Competitive Landscape GlobeNewswire |
| Mar-25-19 04:24PM | Dow Ends Slightly Higher Despite Slowing Global Growth Worries TheStreet.com |
| 03:15PM | 3 Top Healthcare Stocks to Buy Right Now Motley Fool |
| 02:48PM | 1 Surprising Reason Alzheimer's Drugs Remain So Elusive Motley Fool |
| 12:04PM | Dow Jones Recovers After 130-Point Drop; Marijuana Stocks Rally, Led By Cronos Group Investor's Business Daily |
| 10:39AM | Biogen Stock Likely Wont See a Boost From Buybacks, Analysts Say Barrons.com |
| 09:56AM | Biogen announces $5 billion buyback days after shelving Alzheimer's trials Reuters |
| 09:41AM | Biogen Announces $5 Billion Buyback Just Days After Stock Plunge TheStreet.com |
| 09:01AM | Avon and Biogen Gain, and 3 Other Stocks Making Moves Barrons.com |
| 08:49AM | 5 biotech stocks that could be the next big winners MarketWatch |
| 08:32AM | Biogen announces $5 billion buyback days after shelving Alzheimer's trials Reuters |
| 07:26AM | Biogen sets new $5 billion stock repurchase program in aftermath of stock plunge MarketWatch |
| 06:55AM | Biogen stock plummets 28% after company halts Alzheimers trials MarketWatch |
| 04:05AM | Stocks - Viacom Jumps in Premarket, Nike, Apple Drop, Boeing Gains Investing.com |
| Mar-24-19 01:00PM | Is It Safe to Buy Biogen Stock Right Now? InvestorPlace |
| Mar-23-19 12:20PM | The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings And IPOs Benzinga |
| 10:02AM | 2 Biotech Takeout Targets Perfect for Biogen Motley Fool |
| Mar-22-19 06:00PM | Primecap's Biogen Exposure Could Be History Repeating Morningstar |
| 04:47PM | Biogen Skids On Alzheimer's Flop And Unveils Yet Another Study Investor's Business Daily |
| 04:17PM | Current Stock Market Reverses Lower But Apple, Amazon Strong; Boeing 737 Max Probe; Biogen Dives: Weekly Review Investor's Business Daily |
| 01:30PM | Analysts Digest Biogen's Alzheimer's Disappointment: 'There Isn't Much To Be Excited About' Benzinga |
| 10:58AM | Biogen Stock Is Falling Again Because Even a Massive Plunge Doesnt Make it a Bargain Buy Barrons.com |
| 10:57AM | Biogen Stock Crashes on Termination of Alzheimer's Studies Zacks |
| 10:20AM | Biogen Stock Fell Too Far on Unfortunate News InvestorPlace |
| 10:15AM | Company News For Mar 22, 2019 Zacks |
| 10:15AM | PMN.TO: Aducanumab Failed. What Does This Mean for Amyloid Beta? Zacks Small Cap Research |
| 09:55AM | Eisai Launches Confirmatory Late-Stage Trial Of Second Alzheimer's Asset After Setback Benzinga |
| 09:30AM | Biogen stock price target cut to $247 from $341 at SVB Leerink MarketWatch |
| 08:57AM | Biogen stock plunge shows 'investment model in drug development is all wrong,' says former Atena CEO CNBC |
| 08:44AM | Biogen stock downgraded to neutral from buy at UBS MarketWatch |
| 07:56AM | Former Aetna CEO Mark Bertolini on 'Medicare for All': No... CNBC Videos |
| 07:30AM | A $28 Billion Shopping List for Biogen Bloomberg |
| 07:26AM | Biogen and Apples 2000 Crash Share a Common Trait: Taking Stock Bloomberg |
| 07:00AM | Biogens Next Move Could Be an Acquisition Barrons.com |
| 06:28AM | Experts question Alzheimer's treatment strategy after Biogen failure American City Business Journals |
| 05:01AM | Podcast: A 30% Drop for Biotech Company Biogen, and Two Other Numbers You Need to Know Barrons.com |
| 02:05AM | Eisai starts phase 3 trials for second Alzheimer's drug after first's failure Reuters |
| 12:15AM | Asian stocks stumble on doubts over US-China trade deal Associated Press |
| Mar-21-19 10:45PM | Nikkei falls as financials drag; Eisai indicated to dive Reuters -29.23% |
| 09:05PM | Shares of Japan's Eisai swamped with sell orders after ending Alzheimer trials Reuters |
| 05:41PM | The S&P 500 Eked Out a Gain Despite Biogens 29% Plunge Barrons.com |
| 05:05PM | Stock Market Today: Biogen Crushed After Failure of Alzheimer's Drug Motley Fool |
| 05:00PM | Is Biogen a Bad-News Buy Now? Motley Fool |
| 04:47PM | Biogen scraps two Alzheimer drug trials, wipes $18 billion from market value Reuters |
| 04:44PM | Biogen analyst breaks down what investors want from the c... CNBC Videos |
| 04:31PM | US STOCKS-Wall Street rises as Apple, tech shares climb Reuters |
| 04:29PM | Biogen and Guess slide while Darden and Micron rise Associated Press |
| 04:27PM | Biogen Crashes On Alzheimer's Flop Is Its Remaining Pipeline A Dud? Investor's Business Daily |
| 04:26PM | Dow Ends Solidly Higher as Investors Shrug Off Fed Warning of Slowing Growth TheStreet.com |
| 03:58PM | Biogen halted trial could boost M&A activity, says analys... CNBC Videos |
|
|
|
|
| Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis (MS); SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; FLIXABI, an infliximab biosimilar referencing REMICADE; and IMRALDI, an adalimumab biosimilar referencing HUMIRA. In addition, the company offers RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for the treatment of primary progressive MS and relapsing MS, and other anti-CD20 therapies. Further, it is involved in developing BIIB098, Opicinumab, and BIIB061 for MS and neuroimmunology; Aducanumab, Elenbecestat, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB092 and BIIB054 for treating Parkinson's disease and movement disorders; BIIB067, BIIB078, and BIIB110 to treat neuromuscular disorders; BIIB093, TMS-007, and Natalizumab to treat acute neurology; BIIB104 for treating neurocognitive disorders; BIIB074 and BIIB095 for pain; and Dapirolzumab pegol, BG00011, and BIIB059 for treating other diseases, which are under various stages of development. The company offers products through its sales force and marketing groups. Biogen Inc. has collaboration agreements with Genentech, Inc., Eisai Co., Ltd., Alkermes Pharma Ireland Limited, Bristol-Myers Squibb Company, Acorda Therapeutics, Inc., AbbVie Inc., C4 Therapeutics, University of Pennsylvania, Applied Genetic Technologies Corporation, and others. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts. |
|
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| PANGIA ROBERT W | Director | Mar 18 | Option Exercise | 52.22 | 6,114 | 319,273 | 24,701 | Mar 19 04:08 PM | | PANGIA ROBERT W | Director | Mar 18 | Sale | 328.55 | 6,114 | 2,008,755 | 18,587 | Mar 19 04:08 PM | | McKenzie Paul | EVP Pharmaceutical Oper & Tech | Mar 01 | Option Exercise | 0.00 | 568 | 0 | 7,488 | Mar 05 04:17 PM | | ALEXANDER SUSAN H | EVP Chief Legal Officer & Sec. | Feb 22 | Option Exercise | 38.51 | 8,058 | 310,285 | 36,085 | Feb 26 05:09 PM | | Sandrock Alfred | EVP, Chief Medical Officer | Feb 22 | Option Exercise | 0.00 | 1,663 | 0 | 11,148 | Feb 26 05:07 PM | | Ehlers Michael D | EVP, Research and Development | Feb 15 | Option Exercise | 0.00 | 1,685 | 0 | 8,526 | Feb 20 05:54 PM | | ALEXANDER SUSAN H | EVP Chief Legal Officer & Sec. | Feb 15 | Option Exercise | 0.00 | 1,685 | 0 | 28,776 | Feb 20 05:53 PM | | Vounatsos Michel | Chief Executive Officer | Feb 15 | Option Exercise | 0.00 | 5,269 | 0 | 18,914 | Feb 20 06:10 PM | | Sandrock Alfred | EVP, Chief Medical Officer | Feb 15 | Option Exercise | 0.00 | 1,318 | 0 | 10,071 | Feb 20 06:08 PM | | McKenzie Paul | EVP Pharmaceutical Oper & Tech | Feb 15 | Option Exercise | 0.00 | 1,448 | 0 | 7,968 | Feb 20 06:07 PM | | Vounatsos Michel | Chief Executive Officer | Feb 12 | Option Exercise | 0.00 | 6,899 | 0 | 16,267 | Feb 14 06:33 PM | | Sandrock Alfred | EVP, Chief Medical Officer | Feb 12 | Option Exercise | 0.00 | 4,643 | 0 | 9,452 | Feb 14 06:29 PM | | McKenzie Paul | EVP Pharmaceutical Oper & Tech | Feb 12 | Option Exercise | 0.00 | 3,062 | 0 | 7,059 | Feb 14 06:17 PM | | Gregory Ginger | EVP, Human Resources | Feb 12 | Option Exercise | 0.00 | 1,836 | 0 | 2,561 | Feb 14 06:10 PM | | Ehlers Michael D | EVP, Research and Development | Feb 12 | Option Exercise | 0.00 | 3,827 | 0 | 7,639 | Feb 14 06:07 PM | | ALEXANDER SUSAN H | EVP Chief Legal Officer & Sec. | Feb 12 | Option Exercise | 0.00 | 3,268 | 0 | 27,710 | Feb 14 06:04 PM | | DENNER ALEXANDER J | Director | Feb 01 | Buy | 328.45 | 7,000 | 2,299,163 | 524,658 | Feb 01 04:19 PM | | DENNER ALEXANDER J | Director | Jan 31 | Buy | 330.52 | 25,800 | 8,527,393 | 517,658 | Feb 01 04:19 PM | | DENNER ALEXANDER J | Director | Jan 30 | Buy | 324.86 | 30,000 | 9,745,851 | 491,858 | Feb 01 04:19 PM | | CAPELLO JEFFREY D | EVP & Chief Financial Officer | Jan 02 | Option Exercise | 0.00 | 1,331 | 0 | 1,331 | Jan 04 04:17 PM | | Guindo Chirfi | EVP Glob. Mkt Acc & Cust Innov | Dec 01 | Option Exercise | 0.00 | 602 | 0 | 2,721 | Dec 04 08:21 PM | | Ehlers Michael D | EVP, Research and Development | Sep 26 | Sale | 350.00 | 1,000 | 350,000 | 4,281 | Sep 27 04:16 PM | | Gregory Ginger | EVP, Human Resources | Aug 01 | Option Exercise | 0.00 | 262 | 0 | 1,122 | Aug 03 04:14 PM | | Ehlers Michael D | EVP, Research and Development | Jun 01 | Option Exercise | 0.00 | 1,384 | 0 | 5,897 | Jun 05 04:31 PM | | Vounatsos Michel | Chief Executive Officer | May 02 | Option Exercise | 0.00 | 1,687 | 0 | 10,118 | May 04 06:09 PM | | DENNER ALEXANDER J | Director | Apr 25 | Buy | 269.91 | 48,000 | 12,955,680 | 461,858 | Apr 27 07:48 AM |
|
|
|
|
|
|
